Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.
Busch
Christian
C
Geisler
Jürgen
J
Knappskog
Stian
S
Lillehaug
Johan R
JR
Lønning
Per E
PE
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics / Q000378:metabolism*; D003606:Dacarbazine / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D011237:Predictive Value of Tests; D012878:Skin Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*
D018906:Antineoplastic Agents, Alkylating; D019941:Cyclin-Dependent Kinase Inhibitor p16; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D003606:Dacarbazine